ABBVIE
🇫🇷France
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 51
- Registration Number
- NCT01380704
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 222
- Registration Number
- NCT01328626
- Locations
- 🇺🇸
Dana-Farber Cancer Institute /ID# 48324, Boston, Massachusetts, United States
🇺🇸University of Arizona Cancer Center - North Campus /ID# 52902, Tucson, Arizona, United States
🇺🇸Ucsd /Id# 48325, La Jolla, California, United States
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Completed
- Conditions
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 403
- Registration Number
- NCT01329380
- Locations
- 🇯🇵
Teikyo University Hospital, 板橋区, Tokyo, Japan
🇯🇵Ozone Surgery Clinic, Aichi, Japan
🇯🇵Asahikawa Kosei General Hosp, Asahikawa-shi, Japan
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT01225302
To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 27
- Registration Number
- NCT01199224
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 19
- Registration Number
- NCT01192568
- Locations
- 🇺🇸
Loma Linda University /ID# 236889, Loma Linda, California, United States
🇺🇸Albany Medical College /ID# 236880, Albany, New York, United States
🇺🇸Duke University /ID# 237494, Durham, North Carolina, United States
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 424
- Registration Number
- NCT01148225
Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 62
- Registration Number
- NCT01133548
An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT01130298
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT01121133
© Copyright 2024. All Rights Reserved by MedPath